

# *National Institutes of Health Office of Technology Transfer*



## *NIH Women's Health Technologies Available for Licensing*

6011 Executive Boulevard, Suite 325 • Rockville MD 20852-3804  
Phone: 301-496-7057 • Website: [www.ott.nih.gov](http://www.ott.nih.gov) • E-mail [NIHOTT@mail.nih.gov](mailto:NIHOTT@mail.nih.gov)

## INTRODUCTION

NIH has an extensive intellectual property portfolio of early-stage technologies and also invests substantially in their development. Roughly 10 percent of the annual NIH budget is dedicated to intramural research and development activities -- resulting in inventions that form the basis of a variety of new medical technology and therapies in the areas of medical devices, software, vaccines, diagnostics, and reagents. Similar to university research, commercial partners are needed to make sure that the long hours at the lab bench and the public investment pay off in the end in marketed products.

NIH believes that the future development of its innovative, early stage research lies largely with innovative, early stage companies. While the increasingly consolidated pharmaceutical industry remains a steady customer of research reagents and clinical collaborations with NIH, the more exciting therapeutic developments increasingly seem to come from NIH licenses signed with small and medium-sized life science companies early in their growth phase.

To further attract such early-stage concerns and start-ups, NIH affords favorable treatment to small firms and tries to provide IP agreements that facilitate new areas of product development based upon NIH research. For example, financially-burdened smaller companies can benefit from flexibility on patent costs and license execution fees in license agreements. Of particular note for venture-backed firms is that companies do not give up equity or management control nor are their future development or marketing rights compromised by signing NIH license agreements. Finally, once the product is in development, NIH is often able to assist with clinical trials, follow-on research collaborations, and even eventual purchase of the product as a customer.

We have compiled our technologies related to diagnosis and treatment of women related illnesses that your company might be interested in for further discussion with our Licensing and Patenting Managers. Each entry has a link to our web abstract where you will find the contact information for a Licensing and Patenting Manager who can guide you on our licensing process. If you are interested in other technologies please click on the Licensing Opportunities icon on our web page [www.ott.nih.gov](http://www.ott.nih.gov) to access our comprehensive and searchable catalog. For more information or any inquiries please email us at [nihott@od.nih.gov](mailto:nihott@od.nih.gov).

**Method for Preparing 17alpha-acetoxy-11beta-(4,N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, Intermediates Thereof, and Methods for the Preparation of Such Intermediates**

*HHS Reference #:* E-113-2002

*Indication:* Fibroids

**Novel Osteobiologic Proteins for Treatment of Osteoporosis, Rheumatoid and Neurologic Diseases**

*HHS Reference #:* E-138-1994

*Indication:* Osteoporosis

**Isolation And Use Of Tissue Growth-Inducing FRZB Protein**

*HHS Reference #:* E-127-1995

*Indication:* Osteoporosis

**Mutants Having a Deficit of Functional Steroid Hormone Receptors**

*HHS Reference #:* E-210-1992

*Indication:* Osteoporosis

**Biologically Active Macrolides, Compositions and Uses Thereof**

*HHS Reference #:* E-203-2000

*Indication:* Osteoporosis

**Polypeptides Comprising IL-6 Ligand Binding Receptor Domains and Related Nucleic Acids, Antibodies, Compositions and Methods**

*HHS Reference #:* E-061-1999

*Indication:* Osteoporosis

**sFRP and Peptide Motifs That Interact with sFRP and Methods of Their Use**

*HHS Reference #:* E-060-2000

*Indication:* Osteoporosis

**Methods for Treating Active Uveitis**

*HHS Reference #:* E-328-2004

*Indication:* Osteoporosis

**Modulating P38 Kinase Activity**

*HHS Reference #:* E-010-2004

*Indication:* Osteoporosis

**Fluorescent Magnesium Indicators**

*HHS Reference #:* E-067-2000

*Indication:* Osteoporosis

**Potent and Selective Inhibitors of Human Lipoxxygenase for Prostate Cancer Therapy**

*HHS Reference #:* E-252-2009

*Indication:* Osteoporosis

**Fourier X-ray Scattering and Phase-Contrast Imaging: Enhanced Contrast and Sensitivity of X-ray Images**

*HHS Reference #:* E-248-2009

*Indication:* Osteoporosis

**Antibody Composition and Methods for the Prevention and Treatment of Lupus Nephritis**

*HHS Reference #:* E-156-2009

*Indication:* Lupus

**Methods and Compositions for Treating Diseases and Disorders Associated with Natural Killer T-Cells**

*HHS Reference #:* E-282-2002

*Indication:* Lupus

**Transgenic Mouse Model for Lupus and Other Autoimmune Diseases**

*HHS Reference #:* E-128-2007

*Indication:* Lupus

**Mouse Model of Individual Unresponsive to Interferon**

*HHS Reference #:* E-106-2009

*Indication:* Lupus

**Scavenger Receptor BI Targeting for the Treatment of Infection, Sepsis and Inflammation**

*HHS Reference #:* E-008-2003

*Indication:* Lupus

**Methods For Treating Autoimmune Diseases And Transplantation Rejection**

*HHS Reference #:* E-068-1993

*Indication:* Lupus

**Ixodes Salivary Anticomplement Protein**

*HHS Reference #:* E-207-2000

*Indication:* Lupus

**Cell Based Immunotherapy**

*HHS Reference #:* E-312-2008

*Indication:* Lupus

**A Simple Genetic Test for Kidney Disease**

*HHS Reference #:* E-090-2008

*Indication:* Lupus

**Methods for Treating Autoimmune Inflammatory Disease by Blocking DR3-TL1A Interactions**

*HHS Reference #:* E-011-2007

*Indication:* Lupus

**Novel Proteins from the Sand Fly Lutzomyia longipalpis are Potent Inhibitors of Complement Activity**

*HHS Reference #:* E-205-2008

*Indication:* Lupus

**Modulating P38 Kinase Activity**

*HHS Reference #:* E-010-2004

*Indication:* Lupus

**TTP as a Regulator of GM-CSF mRNA**

**Deadenylation and Stability**

*HHS Reference #:* E-204-1999

*Indication:* Lupus

**Methods for Expression and Purification  
of Immunotoxins**

*HHS Reference #:* E-043-1997

*Indication:* Lupus

**qPCR Assay for Detection of JC Virus**

*HHS Reference #:* E-152-2009

*Indication:* Lupus

**Biomarkers for Sjögren's Syndrome**

*HHS Reference #:* E-018-2009

*Indication:* Autoimmune Disease